Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts

Stuart M. Greenstein, Marcela Del Rio, E. Ong, D. Feuerstein, R. Schechner, D. Kim, H. Corey, R. Kaskel, V. A. Tellis, M. L. Moritz

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Recurrence of focal segmental glomerulosclerosis (FSGS) in pediatric renal allografts is associated with a poor graft survival. This study reports on plasmapheresis for the treatment of recurrent FSGS in pediatric renal transplant recipients. The records of 100 consecutive pediatric (age <21 years) renal transplants were reviewed. Twenty patients had FSGS as the cause of renal failure. Eight of these (40%) had a recurrence (proteinuria >1 g/m2 per day) within 1 month of transplantation. Five of six patients treated with plasmapheresis went into remission (<0.2 g/m2 per day), receiving a total of 42±26 (12-73) sessions, with the mean number of sessions required to achieve a remission being 24±17 (8-51). One patient had a second recurrence 1 year following cessation of plasmapheresis and responded to another course of plasmapheresis. The 1 patient who did not respond to plasmapheresis had a delay in initiation of therapy of 42 days. Plasmapheresis initiated within 48 h of recurrence resulted in earlier remissions and improved graft survival among our patients. Plasmapheresis appears to be effective in treating recurrent FSGS following kidney transplantation and should be started as soon as possible. The number of plasmapheresis sessions used to achieve remission should be adjusted according to response rather than adhering to a fixed protocol.

Original languageEnglish (US)
Pages (from-to)1061-1065
Number of pages5
JournalPediatric Nephrology
Volume14
Issue number12
DOIs
StatePublished - 2000

Fingerprint

Plasmapheresis
Sclerosis
Allografts
Pediatrics
Kidney
Focal Segmental Glomerulosclerosis
Graft Survival
Therapeutics
Recurrence
Kidney Transplantation
Transplantation

Keywords

  • Focal sclerosis
  • Nephrotic syndrome
  • Plasmapheresis
  • Proteinuria
  • Recurrence
  • Renal transplantation

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts. / Greenstein, Stuart M.; Del Rio, Marcela; Ong, E.; Feuerstein, D.; Schechner, R.; Kim, D.; Corey, H.; Kaskel, R.; Tellis, V. A.; Moritz, M. L.

In: Pediatric Nephrology, Vol. 14, No. 12, 2000, p. 1061-1065.

Research output: Contribution to journalArticle

Greenstein, SM, Del Rio, M, Ong, E, Feuerstein, D, Schechner, R, Kim, D, Corey, H, Kaskel, R, Tellis, VA & Moritz, ML 2000, 'Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts', Pediatric Nephrology, vol. 14, no. 12, pp. 1061-1065. https://doi.org/10.1007/s004670000378
Greenstein, Stuart M. ; Del Rio, Marcela ; Ong, E. ; Feuerstein, D. ; Schechner, R. ; Kim, D. ; Corey, H. ; Kaskel, R. ; Tellis, V. A. ; Moritz, M. L. / Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts. In: Pediatric Nephrology. 2000 ; Vol. 14, No. 12. pp. 1061-1065.
@article{ac6f3e99fa0f46779ba5ceea5d4a804e,
title = "Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts",
abstract = "Recurrence of focal segmental glomerulosclerosis (FSGS) in pediatric renal allografts is associated with a poor graft survival. This study reports on plasmapheresis for the treatment of recurrent FSGS in pediatric renal transplant recipients. The records of 100 consecutive pediatric (age <21 years) renal transplants were reviewed. Twenty patients had FSGS as the cause of renal failure. Eight of these (40{\%}) had a recurrence (proteinuria >1 g/m2 per day) within 1 month of transplantation. Five of six patients treated with plasmapheresis went into remission (<0.2 g/m2 per day), receiving a total of 42±26 (12-73) sessions, with the mean number of sessions required to achieve a remission being 24±17 (8-51). One patient had a second recurrence 1 year following cessation of plasmapheresis and responded to another course of plasmapheresis. The 1 patient who did not respond to plasmapheresis had a delay in initiation of therapy of 42 days. Plasmapheresis initiated within 48 h of recurrence resulted in earlier remissions and improved graft survival among our patients. Plasmapheresis appears to be effective in treating recurrent FSGS following kidney transplantation and should be started as soon as possible. The number of plasmapheresis sessions used to achieve remission should be adjusted according to response rather than adhering to a fixed protocol.",
keywords = "Focal sclerosis, Nephrotic syndrome, Plasmapheresis, Proteinuria, Recurrence, Renal transplantation",
author = "Greenstein, {Stuart M.} and {Del Rio}, Marcela and E. Ong and D. Feuerstein and R. Schechner and D. Kim and H. Corey and R. Kaskel and Tellis, {V. A.} and Moritz, {M. L.}",
year = "2000",
doi = "10.1007/s004670000378",
language = "English (US)",
volume = "14",
pages = "1061--1065",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts

AU - Greenstein, Stuart M.

AU - Del Rio, Marcela

AU - Ong, E.

AU - Feuerstein, D.

AU - Schechner, R.

AU - Kim, D.

AU - Corey, H.

AU - Kaskel, R.

AU - Tellis, V. A.

AU - Moritz, M. L.

PY - 2000

Y1 - 2000

N2 - Recurrence of focal segmental glomerulosclerosis (FSGS) in pediatric renal allografts is associated with a poor graft survival. This study reports on plasmapheresis for the treatment of recurrent FSGS in pediatric renal transplant recipients. The records of 100 consecutive pediatric (age <21 years) renal transplants were reviewed. Twenty patients had FSGS as the cause of renal failure. Eight of these (40%) had a recurrence (proteinuria >1 g/m2 per day) within 1 month of transplantation. Five of six patients treated with plasmapheresis went into remission (<0.2 g/m2 per day), receiving a total of 42±26 (12-73) sessions, with the mean number of sessions required to achieve a remission being 24±17 (8-51). One patient had a second recurrence 1 year following cessation of plasmapheresis and responded to another course of plasmapheresis. The 1 patient who did not respond to plasmapheresis had a delay in initiation of therapy of 42 days. Plasmapheresis initiated within 48 h of recurrence resulted in earlier remissions and improved graft survival among our patients. Plasmapheresis appears to be effective in treating recurrent FSGS following kidney transplantation and should be started as soon as possible. The number of plasmapheresis sessions used to achieve remission should be adjusted according to response rather than adhering to a fixed protocol.

AB - Recurrence of focal segmental glomerulosclerosis (FSGS) in pediatric renal allografts is associated with a poor graft survival. This study reports on plasmapheresis for the treatment of recurrent FSGS in pediatric renal transplant recipients. The records of 100 consecutive pediatric (age <21 years) renal transplants were reviewed. Twenty patients had FSGS as the cause of renal failure. Eight of these (40%) had a recurrence (proteinuria >1 g/m2 per day) within 1 month of transplantation. Five of six patients treated with plasmapheresis went into remission (<0.2 g/m2 per day), receiving a total of 42±26 (12-73) sessions, with the mean number of sessions required to achieve a remission being 24±17 (8-51). One patient had a second recurrence 1 year following cessation of plasmapheresis and responded to another course of plasmapheresis. The 1 patient who did not respond to plasmapheresis had a delay in initiation of therapy of 42 days. Plasmapheresis initiated within 48 h of recurrence resulted in earlier remissions and improved graft survival among our patients. Plasmapheresis appears to be effective in treating recurrent FSGS following kidney transplantation and should be started as soon as possible. The number of plasmapheresis sessions used to achieve remission should be adjusted according to response rather than adhering to a fixed protocol.

KW - Focal sclerosis

KW - Nephrotic syndrome

KW - Plasmapheresis

KW - Proteinuria

KW - Recurrence

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=0033813660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033813660&partnerID=8YFLogxK

U2 - 10.1007/s004670000378

DO - 10.1007/s004670000378

M3 - Article

C2 - 11045387

AN - SCOPUS:0033813660

VL - 14

SP - 1061

EP - 1065

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 12

ER -